Quantcast

Latest Therapeutic angiogenesis Stories

2011-08-18 12:27:00

CAMBRIDGE, Mass., Aug. 18, 2011 /PRNewswire/ -- Leading angiogenesis and cancer researcher Dr. Robert S. Kerbel of the University of Toronto will deliver the Future of Medicine Keynote Address at the Angiogenesis Foundation's 9th International M. Judah Folkman Conference -- New Frontiers in Therapeutic Development. The conference will take place on October 29-30, 2011 in Cambridge, MA, and attracts key opinion leaders from academia, industry and government to discuss the latest scientific...

2011-05-11 09:12:00

CAMBRIDGE, Mass., May 11, 2011 /PRNewswire/ -- The Angiogenesis Foundation has opened early registration for its 2011 Antiangiogenesis Conference that will take place on October 29-30 in Cambridge, MA. The 9th International M. Judah Folkman Conference -- New Frontiers in Therapeutic Development attracts key opinion leaders from academia, industry, government, and patient advocacy to discuss the latest information about research and therapeutic development in antiangiogenic therapy for...

2011-04-18 13:03:10

Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9 (FGF9), is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged...

2009-06-17 08:00:00

SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced it is scheduled to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 26, 2009 according to a preliminary list of additions posted on www.russell.com. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S....

2009-05-12 08:15:00

SAN DIEGO, May 12 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that the Company will hold a conference call and webcast to discuss recent developments and future plans for its Excellarate(TM) clinical development program. (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO) On May 6, 2009, the Company announced the completion of recruitment for the Tissue Repair Company's pioneering gene therapy Phase 2b MATRIX clinical trial to evaluate the...

2009-03-05 17:25:00

SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Alternext US: CXM) today announced the completion of a $3.5 million credit facility in the form of debt with accompanying warrants to purchase shares of common stock. Empire Asset Management Company acted as financial advisor and sole placement agent for the transaction. The material terms of the credit facility are described in more detail in the Company's Current Report on Form 8-K to be filed with the Securities and...

2009-02-03 08:00:00

SAN DIEGO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE: CXM) today reported on recent clinical findings published in The New England Journal of Medicine showing the long-term outcome of a method of gene therapy to treat infant children with a fatal disorder of the immune system. The infant children studied had a rare form of severe combined immunodeficiency (SCID). SCID arises in infants with a genetic defect that leaves them unable to produce an enzyme called...

2009-01-26 17:44:00

SAN DIEGO, Jan. 26 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Alternext US: CXM) today reported that Ronald I. Simon (age 70) has retired from the Company's Board of Directors. The resignation reduces the size of Cardium's board to seven directors. "We thank Dr. Simon for his service to the Board and wish him all the best in the years ahead," stated Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics. (Logo:...

2008-06-30 09:03:37

SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Cardium Therapeutics announced that it has completed a registered direct offering with an institutional investor that participated in its prior financing for the purchase of shares of its common stock and warrants to purchase additional shares of common stock. The transaction resulted in gross proceeds to Cardium of approximately $3.25 million, before placement agent fees and offering expenses and excluding any future proceeds from the exercise...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related